Around 75% of breast cancers are defined and driven by ERα transcriptional activity and for decades, anti-oestrogen therapies targeting ER have formed the cornerstone of therapy for the management of ER+ breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.